[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transgender\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transgender":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,76,97,118,149,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100464991","sex-differential-host-microbiome-cvd-risk---a-longitudinal-cohort-approach-100464991",false,"NCT05334888","Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach","Sex Hormone-specific Cardiovascular Risks in the Gut Microbiome-host Axis - A Longitudinal Cohort Study.","XCVD","Inclusion Criteria:\n\n* Age 18-50\n* Language requirements: German, English\n* Previous gender hormone replacement therapy (HRT).\n* Ability to give consent and written consent to participate.\n* Health insurance (for clarification of incidental findings)\n\nExclusion Criteria:\n\n* Diseases or functional disorders that, in the opinion of the study physician, preclude participation in the study.\n* Incapacity or other circumstances that do not allow study participants to fully understand the nature, significance and scope of this study.","ALL","18 Years","50 Years",{"count":21,"type":22},200,"ESTIMATED","2 Years","OBSERVATIONAL","The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for five years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.",[27,28,29,30],"Transgender","Gut Microbiome","Immune System","Cardiovascular Risk Factors",[32],"Transgender Medicine","RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2022-08-29",{"date":41,"type":22},"2030-12-31",{"name":43,"class":44},"Charite University, Berlin, Germany","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100612369","the-effect-of-gender-affirmative-measures-on-breast-perception-in-trans-men-100612369","NCT07252687","The Effect of Gender-affirmative Measures on Breast Perception in Trans Men","The Effect of Gender-affirmative Measures on Breast Perception in Trans Men (TRANSBREAST) - a Prospective Cohort Study","TRANSBREAST","Inclusion Criteria:\n\n* AFAB (Assigned Female At Birth)\n* before starting GAHT\n* before mastectomy\n\nExclusion Criteria:\n\n* Ongoing GAHT\n* Mastectomy already performed\n* Lack of capacity to give consent\n* Insufficient knowledge of German","FEMALE","16 Years",{"count":57,"type":22},100,"Breast dysphoria in transmasculine or genderdiverse individuals is a distinct psychological burden associated with depression, anxiety and suicidality. The aim is to systematically investigate the effect of GAHT (gender-affirming hormone therapy) and mastectomy on this form of dysphoria.\n\nThe primary objective of this study is to analyse and investigate the psychological and physical effects of breast development on trans men or genderdiverse individuals.\n\nA secondary objective is to determine the extent to which the stress affects the well-being of trans men depending on the coping strategies used (binding vs. taping).",[27,60],"Gender Dysphoria in Adolescents and Adults",[62,63,64,65,66],"transgender","breastdysphoria","trans male","non binary","genderdiverse","2026-03-04",{"date":69,"type":37},"2026-03-06",{"date":71,"type":37},"2025-11-30",{"date":73,"type":22},"2030-11",{"name":75,"class":44},"Medical University Innsbruck",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100620536","gender-affirming-hormone-therapy-and-immune-function-in-trans-individuals---the-gift-study-100620536","NCT07358897","Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study","GIFT","Inclusion Criteria:\n\n* Adults between 18 and 50 years of age with diagnosed gender dysphoria about to start gender-affirming hormone therapy with either oestrogen or testosterone.\n\nExclusion Criteria:\n\n* Lack of capacity to consent.\n* Abnormalities in expected pubertal development and pharmacological interventions that could affect levels of gonadal steroids including suspected or confirmed self-treatment with steroid hormone preparations in preceding month (birth control excluded).\n* Serious immunological disease (immune deficiency, autoimmune disease requiring immunomodulatory treatment).\n* Regular immunomodulatory treatment such as prednisolone or biological drugs.\n* In the case of vaccination or symptomatic infection ≤5 days before the visit blood sampling should be postponed by 1 week.\n* Age \\\u003C18 years or \\>50 years\n* Completed menopause (persons assigned female sex at birth).\n* Positivity for blood borne viruses (HIV, Hepatitis B, Hepatitis C, HTLV-1)",{"count":84,"type":22},500,"Our immune systems protect us from infection but can also cause disease, for example by attacking our own bodies (autoimmune disease), or driving chronic inflammation in conditions such as heart disease. The immune systems of men and women function differently, as evidenced by differing rates of disease with autoimmune disease being more common in women whilst men are more susceptible to infection. We don't know why these differences exist, but if we could understand we may be able to develop new treatments to treat or prevent immune driven diseases. So far, we know that both sex chromosomes and hormones affect how the immune system functions, but not the exact contribution of each or how they interact. One way to study this is to work with transgender people. Transgender people identify as a gender different from their sex assigned at birth and some may choose to take the sex hormones of the gender they identify with, which is known as gender affirming hormone therapy (GAHT). Given that these changes affect their sex hormone profile and not their chromosomes, any changes in their immune system would be driven by hormones only. This would help us understand not only how sex hormones shape the immune system more generally, but also the disease risk in transgender people and enable better patient counselling. In this study, transgender patients starting on GAHT at 56 Dean Street clinic in London would be invited to donate blood samples before starting therapy, at 1 month (optional) and at 3 and 6 months. These samples would be analysed at the Laboratory of Medical Sciences to examine how the different types of immune cells change with therapy and how they respond to different immune triggers (stimuli). We aim to recruit 500 individuals and anticipate the study will last up to 3 years.",[27],"NOT_YET_RECRUITING","2026-01-14",{"date":90,"type":37},"2026-01-22",{"date":92,"type":22},"2026-02-16",{"date":94,"type":22},"2029-01-07",{"name":96,"class":44},"Imperial College London",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100598764","cervical-and-endometrial-cancer-screening-in-patients-seeking-gender-affirming-hysterectomy-100598764","NCT07075731","Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy","Inclusion Criteria:\n\n* 18 years and older\n* Able to provide voluntary written consent prior to the performance of any research related activity. Patients who can provide informed consent\n* Able to understand, speak, read, and write in English\n* Patients who have undergone hysterectomy, or plan to have a hysterectomy\n* Patients who are transgender and gender diverse\"\n\nExclusion Criteria:\n\n* Opted out of research\n* \\\u003C18 years old\n* Lacks capacity to consent\u002Fhas diminished capacity to consent\n* Cannot provide informed consent\n* Those on the study's community advisory board",{"count":104,"type":22},40,"This study aims to quantify the rates of cervical cancer screening and endometrial sampling prior to gender-affirming hysterectomy, assess the need for these tests in TGD individuals, and explore patient-centered options for these tests. By assessing the status of testing and correlation with hysterectomy pathology, this study will provide preliminary data on the current state of guideline-concordant care and provide initial evidence for the development of evidence-based guidelines in the future",[107,27,108],"Cancer Screening","Gender Diverse Populations","2025-07-10",{"date":111,"type":37},"2025-07-20",{"date":113,"type":37},"2025-06-30",{"date":115,"type":22},"2027-06-30",{"name":117,"class":44},"University of Minnesota",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":45},"100567581","puberty-testosterone-and-brain-development-100567581","NCT06670053","Puberty, Testosterone, and Brain Development","Effect of Testosterone on Brain Imaging and Headache in Transmasculine Adolescents","Inclusion Criteria:\n\n1. transmasculine and gender diverse\n2. assigned female at birth\n3. age 12-20 years at the time of enrollment\n4. plan to start testosterone clinically in \\\u003C 6 months\n5. if taking gonadotropin releasing hormone agonist (GnRHa, puberty blocker), was started on this type of drug 3+ months prior to enrollment\n\nExclusion Criteria:\n\n1. cognitive or psychiatric impairment resulting in inability to tolerate or perform the study procedures\n2. known history of stroke, multiple sclerosis, or other serious neurologic condition\n3. prior diagnosis of Turner Syndrome (monosomy X) or other difference of sexual development\n4. prior diagnosis of polycystic ovarian syndrome (PCOS)\n5. uncontrolled or untreated hypothyroidism\n6. MRI-specific exclusion criteria: (Weight \\> 500 lbs, severe claustrophobia, certain type of metal in body)","12 Years","20 Years",{"count":57,"type":22},"Transmasculine youth (female sex assigned at birth, male gender identity) who begin clinical gender affirming hormone therapy (GAHT) with testosterone (T) may experience changes in headache. Researchers think this because studies published on effects of giving testosterone to cisgender females (female sex, female gender identity) and transmasculine adults seem to show an effect on pain.\n\nThis research will help us learn more about changes in headache and in brain structure and function in transmasculine youth during the first two years of T. Youth who will be starting T within 6 months, either on puberty blocker or not, as part of their regular medical care can participate and will be asked to attend 4 visits:\n\n* before starting T\n* after 6 months on T\n* after 1 year on T\n* after 2 years on T\n\nAt the visits, they will be asked to:\n\n* answer questions and surveys about their health\n* have a brain MRI done\n* give a small sample of blood\n\nand at their first visit, complete a physical exam. Some participants can also do a brief test of pain sensitivity. All participants will be asked to complete a headache diary for the first 6 months, for 1 month after the 1 year visit, and for 1 month after the 2 year visit.",[130,60,131,27],"Gender Identity","Headache",[133,134,135,136,137,138,139],"resting-state functional connectivity","pain task","fMRI","MRI","migraine","gender affirming hormone therapy","testosterone","2025-04-02",{"date":142,"type":37},"2025-04-03",{"date":144,"type":37},"2024-12-31",{"date":146,"type":22},"2026-12",{"name":148,"class":44},"University of Colorado, Denver",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100463750","china-gender-affirming-hormone-therapy-study-100463750","NCT05318755","China Gender-affirming Hormone Therapy Study","China Gender-affirming Hormone Therapy Study in Transgender Men and Women","CGAHT","Inclusion Criteria:\n\n* Transgender men and women\n* Meet criteria of Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) for gender dysphoria\n* Aged between 18 to 40 years\n* People desire to start the GAHT\n* No previous history of gender-affirming interventions\n* Having full ability to make informed consent\n* Dextromanual\n\nExclusion Criteria:\n\n* Disorders of sex development\n* Who has fertility demand but have not made fertility preservation\n* With contradictions of GAHT\n* Comorbid diseases are not under control\n* Alcohol or drug abuse\n* Hormonal and chromosomal disorders\n* History of gender affirming surgery\n* Current psychiatric disorders\n* History of brain trauma or neurological pathologies\n* Current use of medications with psychotropic effects within two weeks (antipsychotic or antiepileptic agents, lithium, benzodiazepines or opioid analgesics)\n* Claustrophobia\n* Implanted metal and medical devices (pacemakers, ceramic teeth, etc.),\n* Tattoos or eyebrow tattooing (heavy metal dye)",true,"40 Years",{"count":160,"type":22},240,"Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.",[27,163],"Gender Incongruence",[165,166],"Transgender Persons","Gender-affirming Hormone Therapy","2024-11-05",{"date":169,"type":37},"2024-11-07",{"date":171,"type":37},"2022-04-16",{"date":173,"type":22},"2028-12-31",{"name":175,"class":44},"Peking University Third Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":157,"sex":183,"minAge":18,"maxAge":19,"enrollmentInfo":184,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":45},"100556890","the-effect-of-tucking-on-semen-quality-of-adult-trans-women-100556890","NCT06530992","The Effect of Tucking on Semen Quality of Adult Trans Women","The Effect of Tucking on Semen Quality of Adult Trans Women Compared to Semen Quality of Trans Women Who do Not Tuck - a Case Control Study","Inclusion Criteria:\n\n* Female transgender patients between the ages of 18 to 50 years of age who are seen at the University Clinic for Gyn. Endocrinology and Reproductive Medicine of the Medical University of Innsbruck. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy\n\nExclusion Criteria:\n\n* Ongoing GAHT gender affirming genital surgery Hypogonadism Diabetes mellitus Cystic Fibrosis Varicocele Cryptorchism Post-sterilization Incapacity to consent","MALE",{"count":104,"type":22},"Because gender-affirming hormone therapy (GAHT) can lead to fertility impairment, current guidelines and treatment recommendations require that patients be informed about the possibility of fertility preservation prior to initiating GAHT. A recent review by our working group analyzed the current data on fertility and fertility preservation in transgender and gender diverse people. Several studies were identified that evaluated semen quality before and during GAHT in trans women compared to reproductive men. All studies showed a significant reduction in semen quality even before GAHT. In addition, one study found evidence that constant wearing of tight underwear and tucking was associated with a reduction in motile sperm concentration to \\\u003C5 mill\u002Fml. Tucking is a method of avoiding crotch bulge through the penis and testicles by placing the penis backwards between the legs and optionally pushing the testicles into the groin canals. These positions are fixed with tight-fitting underwear or gaffs. Whether tucking or the wearing of tight underwear is the determining factor for impaired semen quality even before the start of GAHT and whether there is reversibility remains unclear and will be investigated in the present study.\n\nThe study is designed as a prospective case-control study with a total sample size of n = 40 trans women. All patients with gender incongruence presenting to the University Clinic for Gynecology, Endocrinology and Reproduction Innsbruck before starting GAHT are eligible to participate. Trans women (n = 20) who practice tucking or wear tight underwear will be included and trans women (n = 20) who do not practice tucking will be included as a control group. At Time 1, after 2-7 days of abstinence, all participants will provide a semen sample for a spermiogram, a venous blood sample will be taken, and quality of life will be assessed using a questionnaire. The frequency and duration of tucking or wearing tight underwear, ejaculation frequency, demographic data such as BMI, nicotine use, alcohol and drug use, medication use, underlying medical conditions, previous surgeries, etc. are also recorded.\n\nParticipants in the study group are then asked to abstain tucking for at least 73 days. After 2-7 days of sperm abstinence, another semen sample is taken at time 2, a venous blood sample is taken, and quality of life is assessed. At this point, depending on the participant's wishes, there is the option of sperm cryopreservation for fertility preservation prior to starting GAHT.\n\nSpermiograms are performed under standardized conditions according to current WHO guidelines.",[27,163,187],"Fertility Issues","2024-07-29",{"date":190,"type":37},"2024-07-31",{"date":192,"type":37},"2024-07-17",{"date":194,"type":22},"2029-12",{"name":75,"class":44}]